ZEPOSIA® is the commercial brand name of Ozanimod Hydrochloride Capsules, an orally active sphingosine-1-phosphate (S1P) receptor modulator developed by Bristol Myers Squibb. It selectively binds to S1P1 and S1P5 receptors on lymphocytes, traps lymphocytes within lymph nodes and limits their…
XTANDI® is the commercial brand name of Enzalutamide Soft Capsules, an orally active, second-generation non-steroidal androgen receptor inhibitor developed by Astellas Pharma. It exerts anti-tumor activity by competitively inhibiting androgen binding to the androgen receptor, blocking nuclear translocation of the…
On May 29, the official website of the National Medical Products Administration (NMPA) announced that two imported innovative drugs have obtained marketing approval in China. The first is Naldemedine Tosylate (brand name: Symproic®), a new therapeutic agent for opioid-induced constipation…
ODOMZO® is the commercial brand name of Sonidegib Phosphate Capsules, an orally active Hedgehog pathway inhibitor developed by Sun Pharmaceutical Industries. It exerts anti-tumor activity by binding to and inhibiting the Smoothened (SMO) receptor, thereby blocking aberrant activation of the…
NINLARO® is the commercial brand name of Ixazomib Citrate Capsules, an orally active, reversible proteasome inhibitor developed by Takeda Pharmaceuticals. It exerts anti-tumor activity by inhibiting the chymotrypsin-like activity of the 20S proteasome, thereby disrupting the ubiquitin-proteasome pathway, inducing endoplasmic…
Retsevmo® is the commercial brand name of Selpercatinib Capsules, an orally active, highly selective rearranged during transfection (RET) inhibitor developed by Eli Lilly and Innovent Biologics. It exerts anti-tumor activity by specifically inhibiting the kinase activity of RET, thereby blocking…
SUTENT® is the commercial brand name of Sunitinib Malate Capsules, an orally active, multi-targeted tyrosine kinase inhibitor (TKI) developed by Pfizer. It exerts anti-tumor activity by inhibiting multiple receptor tyrosine kinases, including VEGFR, PDGFR, KIT, FLT3, and RET, thereby suppressing…
AUGTYRO® is the commercial brand name of Repotrectinib Capsules, a next-generation, orally active, highly selective dual inhibitor of tropomyosin receptor kinase (TRK) and rearranged during transfection (RET) developed by Bristol Myers Squibb. It exerts anti-tumor activity by potently inhibiting the…
GAVRETO® is the commercial brand name of Pralsetinib Capsules, an orally active, highly selective rearranged during transfection (RET) inhibitor developed by Blueprint Medicines and licensed to BeiGene. It exerts anti-tumor activity by specifically inhibiting the kinase activity of RET, thereby…
VITRAKVI® is the commercial brand name of Larotrectinib Sulfate Capsules, a highly selective tropomyosin receptor kinase (TRK) inhibitor developed by Bayer. It exerts anti-tumor activity by specifically inhibiting the kinase activity of tropomyosin receptor kinases (TRKA, TRKB, TRKC) encoded by…